Therapeutic management of patients with chronic stenosis of the larynx and trachea

The treatment of patients with chronic stenosis of the larynx and trachea is a laborious long process that requires special attention to the choice of surgical tactics and conservative therapy. The effectiveness of the performed surgical treatment largely depends on the course of the postoperative wound process, which explains the need for an individual approach to patient management in order to prevent the development of bacterial complications. One of the factors contributing to the occurrence of these complications are transient microorganisms that colonize the mucous membrane of the respiratory tract, represented mainly by Streptococci, Staphylococci and Neisseria, as well as Acinetobacter, Moraxella, Corinebacterium, Escherichia, Klebsiella. In order to prevent postoperative complications, it is necessary to carry out antibacterial prophylaxis with I–II generation cephalosporins (cefazolin, cefuroxime) or inhibitor-protected aminopenicillins (amoxicillin/clavulanate, ampicillin/sulbactam) during clean surgical interventions. In cases where a bacteriological examination reveals hospital strains of microorganisms, it is necessary to carry out antibacterial therapy aimed at eradication of the bacterial pathogen. In case of “dirty” surgical interventions in patients in cases where a bacteriological examination does not reveal pathogenic strains of microorganisms, it is recommended to carry out antibacterial therapy with broad-spectrum antibiotics, within 7–10 days after the surgery. Irrigation and inhalation therapy occupies a special place in the treatment of patients with chronic stenosis of the larynx and trachea. At the final stages of the operation, irrigation of the surgical area with solutions of glucocorticosteroids and anesthetics is used, and inhalation therapy is used starting from the early postoperative period, continuing throughout the entire period of inpatient treatment, as well as at the outpatient stage. Among the inhalation drugs used topic antibiotics, glucocorticosteroids, mineral water, mucolytics, and bacteriophages are most often used.

1. Kryukov A.I., Kunelskaya N.L., Kirasirova E.A., Mamedov R.F., Lafutkina N.V, Rezakov R.A. et al. Selection of the optimal method for surgical treatment of cicatricial stenosis of the larynx and trachea. Practice Guidelines. Moscow; 2020. 21 p. (In Russ.) Available at: https://mosgorzdrav.ru/ru-RU/professional/scientific-activity/methodical.html.

2. Ryabova M.A., Posobilo E.E. Causes of development of cicatrical laryngeal stenosis. Uchenyye zapiski Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta imeni akademika I.P. Pavlova = The Scientific Notes of the Pavlov University. 2015;22(3):17–19. (In Russ.) doi: 10.24884/1607-4181-2015-22-3-17-19.

3. Gelbard A., Francis D.O., Sandulache V.C., Simmons J.C., Donovan D.T., Ongkasuwan J. Causes and consequences of adult laryngotracheal stenosis. Laryngoscope. 2015;125(5):1137–1143. doi: 10.1002/lary.24956.

4. Grillo H.C. (eds.). Surgery of the Trachea and Bronchi. London: BC Decker Inc. Hamilton; 2004. 700 p. doi: 10.1097/01.sla.0000226043.56534.fe.

5. Ashiku S.K., Kuzucu A., Grillo H.C., Wright C.D., Wain J.C., Lo B., Mathisen D.J. Idiopathic laryngotracheal stenosis: effective definitive treatment with laryngotracheal resection. J Thorac Cardiovasc Surg. 2004;127(1):99–107. doi: 10.1016/j.jtcvs.2002.11.001.

6. Jordá C., Peñalver J.C., Escrivá J., Cerón J., Padilla J. Dilatación traqueal neumática en el tratamiento de la estenosis traqueal idiopática [Balloon dilatation of the trachea as treatment for idiopathic tracheal stenosis]. Arch Bronconeumol. 2007;43(12):692–694. doi: 10.1016/S1579-2129(07)60156-6.

7. Herrington H.C., Weber S.M., Andersen P.E. Modern management of laryngotracheal stenosis. Laryngoscope. 2006;116(9):1553–1557. doi: 10.1097/01.mlg.0000228006.21941.12.

8. Timmis K., Jebok F., Rohde M., Molinari G. Microbiome yarns: the Global Phenotype-Genotype Survey: Episode II: laryngeal microbiota and vocal phenotypes (or diction and addiction). Microb Biotechnol. 2019;12(2):191– 199. doi: 10.1111/1751-7915.13375.

9. Kovalik A.P. Microflora of laryngeal mucosa in the healthy subjects and the patients presenting with non-specific post-intubation laryngeal granuloma. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology. 2015;80(5):34–37. (In Russ.) doi: 10.17116/otorino201580534-37.

10. Pal’chun V.T., Lapchenko A.S., Muratov D.L. (eds.). Inflammatory diseases of the larynx and their complications. Moscow: GEOTAR-Media; 2010. (In Russ.)

11. Simoni P., Wiatrak B.J. Microbiology of stents in laryngotracheal reconstruction. Laryngoscope. 2004;114(2):364–367. doi: 10.1097/00005537-200402000-00034.

12. Squire R., Brodsky L., Rossman J. The role of infection in the pathogenesis of acquired tracheal stenosis. Laryngoscope. 1990;100(7):765–770. doi: 10.1288/00005537-199007000-00013.

13. Hillel A.T., Tang S.S., Carlos C., Skarlupka J.H., Gowda M., Yin L.X. et al. Laryngotracheal Microbiota in Adult Laryngotracheal Stenosis. mSphere. 2019;4(3):e00211-19. doi: 10.1128/mSphereDirect.00211-19.

14. Perkins J., Mouzakes J., Pereira R., Manning S. Bacterial biofilm presence in pediatric tracheotomy tubes. Arch Otolaryngol Head Neck Surg. 2004;130(3):339–343. doi: 10.1001/archotol.130.3.339.

15. Brown M.T., Montgomery W.W. Microbiology of tracheal granulation tissue associated with silicone airway prostheses. Ann Otol Rhinol Laryngol. 1996;105(8):624–627. doi: 10.1177/000348949610500807.

16. Kirasirova E.A., Gurov A.V., Rezakov R.A., Ekaterinchev V.A., Lafutkina N.V., Gogoreva N.R., Mamedov R.F. The influence of the tracheal stents on the microbiocenoses of the larynx and trachea at different duration of the cannula-bearing period. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology. 2014;(4):7–12. (In Russ.) Available at: https://www.mediasphera.ru/issues/vestnik-otorinolaringologii/2014/4/030042-4668201442.

17. Bratzler D.W., Houck P.M. Surgical Infection Prevention Guideline Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg. 2005;189(4):395–404. doi: 10.1016/j.amjsurg.2005.01.015.

18. Strachunskiy L.S., Belousov Yu.B., Kozlov S.N. (eds.). A practical guide to anti-infective chemotherapy Smolensk: MAKMAKH; 2007. 462 p. (In Russ.) Available at: https://elib.vsmu.by/bitstream/123/12632/1/Kozlovskij-VI_Nebulajzernaia_terapiia_2014.pdf.

19. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother. 2001;45(4):999–1007. doi: 10.1128/AAC.45.4.999-1007.2001.

20. Bratzler D.W., Dellinger E.P., Olsen K.M., Perl T.M., Auwaerter P.G., Bolon M.K. et al. Clinical Practice Guidelines for antimicrobial prophylaxis in surgery. American Journal of Health-System Pharmacy. 2013;70(3):195–283. doi: 10.2146/ajhp120568.

21. Jones S.M., Morgan M., Humphrey T.J., Lappin-Scott H. Effect of vancomycin and rifampicin on meticillin-resistant Staphylococcus aureus biofilms. Lancet. 2001;357(9249):40–41. doi: 10.1016/S0140-6736(00)03572-8.

22. Kryukov A.I., Kunelskaya N.L., Kirasirova E.A., Mamedov R.F., Lafutkina N.V., Rezakov R.A. et al. Prevention of complications of tracheostomy in patients with temporary and permanent cannulation. Moscow; 2020. (In Russ.) Available at: https://mosgorzdrav.ru/ru-RU/professional/scientific-activity/methodical.html.

23. Smith M.M., Cotton R.T. Diagnosis and management of laryngotracheal stenosis. Expert Rev Respir Med. 2018;12(8):709–717. doi: 10.1080/17476348.2018.1495564.

24. Kostyukova E.A., Kryuchkova O.N., Zhukova N.V., Zakharova M.A., Lebed E.I. Nebulizer therapy in pulmonology. Opportunities and prospects. Krymskiy terapevticheskiy zhurnal = Crimean Journal of Internal Diseases. 2014;2(23):74–81. (In Russ.) Available at: https://cyberleninka.ru/article/n/nebulayzernaya-terapiya-v-pulmonologii-vozmozhnosti-i-perspektivy/viewer.

25. Kozlovskij V.I., Selezneva O.M. Nebulizer therapy. Vitebsk: VGMU; 2014. 83 p. (In Russ.) Available at: https://elib.vsmu.by/bitstream/123/12632/1/Kozlovskij-VI_Nebulajzernaia_terapiia_2014.pdf.

26. Karpova E.P., Tulupov D.A. Biofilms in otorhinolaryngology. Effektivnaya farmakoterapiya. Pediatriya = Effective Pharmacotherapy. Pediatrics. 2012;(1):6–9. (In Russ.) Available at: https://umedp.ru/articles/bakterialnye_bioplenki_v_otorinolaringologii.html.

27. Ari A., Fink J.B. Inhalation therapy in patients with tracheostomy: a guide to clinicians. Expert Rev Respir Med. 2017;11(3):201–208. doi: 10.1080/17476348.2017.1289843.

28. Muchão F.P., Filho L.V. Advances in inhalation therapy in pediatrics. J Pediatr (Rio J). 2010;86(5):367–376. doi: 10.2223/JPED.2024.

29. Pérez-Giraldo C., Rodríguez-Benito A., Morán F.J., Hurtado C., Blanco M.T., Gómez-García A.C. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J Antimicrob Chemother. 1997;39(5):643–646. doi: 10.1093/jac/39.5.643.

30. Olofsson A.C., Hermansson M., Elwing H. N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Appl Environ Microbiol. 2003;69(8):4814–4822. doi: 10.1128/aem.69.8.4814-4822.2003.

31. Rizzato G. Antibiotics for aerosol intake in respiratory infections: pole position for thiamfenicol. L’Internista J. 2001;(9):120.